How to Choose an IP Litigation Firm in Canada (2026): 8 Questions Pharma & Biotech Boards Should Ask

IP litigation lawyers Canada boards retain in 2026 will operate in a materially different environment than they did even two years ago, and the choice of counsel now carries strategic weight that extends well beyond the courtroom. The Canadian Intellectual Property Office (CIPO) has continued to refine its practice guidance, patented medicines disputes remain among the most consequential proceedings a pharmaceutical or biotech company will ever face, and the growing role of digital and AI-derived evidence is reshaping how patent cases are prepared and defended. For directors, general counsel and chief IP officers, selecting the right litigation firm is a governance decision as much as a legal one.

This guide translates that decision into a concrete, board-ready process: eight questions to ask, a scoring matrix to compare firms objectively, and a clear view of costs, funding and due diligence.

Introduction, who this guide is for and what it delivers

The market for ip litigation lawyers Canada companies can call on is deep, but the pool of counsel with current, demonstrable pharmaceutical and biotechnology experience is far narrower. Pharma and biotech boards face disputes where a single patent can underpin an entire product franchise, where regulatory approval timelines and litigation timelines run in parallel, and where the technical evidence is unusually complex. This guide is built for the people who authorise and oversee those engagements: directors weighing risk and cost, general counsel running the procurement process, and chief IP officers assessing technical fit. It is deliberately neutral and practitioner-led.

Rather than profiling firms, it gives you a structured method to interrogate any firm, score its responses, and defend your selection to a board or audit committee. Throughout, the emphasis is on evidence you can request and verify, recent case records, expert-management track records, staffing plans and budget history, rather than reputation alone.

Why 2026 changes to IP practice matter for counsel selection

Evidence capsule: Patented medicines litigation in Canada is governed by the Patented Medicines (Notice of Compliance) Regulations (SOR/93-133) and the Patent Act (R.S.C., 1985, c. P-4), with most substantive proceedings heard in the Federal Court. CIPO issues practice guidance that shapes patent prosecution and, increasingly, the treatment of evidence.

The regulatory backdrop for patent disputes is not static, and 2026 has brought renewed attention to how CIPO’s practice guidance interacts with litigation strategy. CIPO continues to publish practice notices that influence how patents are prosecuted, maintained and, critically, how documentary and technical evidence is handled. Counsel who track these developments closely are better positioned to anticipate how procedural expectations translate into trial preparation. When boards evaluate ip litigation lawyers Canada firms put forward, the currency of a firm’s regulatory knowledge should be treated as a core selection criterion, not a background assumption.

Three forces make 2026 a distinctive moment. First, PM(NOC) litigation under the PM(NOC) Regulations remains the central battleground for brand-name and generic pharmaceutical companies alike, and, following the 2017 amendments that converted PM(NOC) matters into full actions with final determinations of patent validity and infringement, the procedural framework rewards counsel who understand its statutory deadlines and its interaction with regulatory approval. Second, the intersection of patent litigation and Health Canada’s drug approval process means that timing decisions in one forum can have decisive consequences in the other.

Third, the rise of AI-generated and large-volume digital evidence has changed what “handling the evidence” actually requires, from chain-of-custody and data-integrity questions to the retention of technical experts who can speak to how such evidence was created.

For a board, the practical implication is straightforward. A firm whose PM(NOC) experience predates the 2017 reforms, or whose evidence practices have not adapted to digital and AI-derived material, may be technically competent yet strategically behind. The selection process should therefore probe recency and adaptation directly, and the questions below are designed to surface exactly that.

Who should lead selection, board oversight vs. GC-driven process

Choosing outside counsel for high-stakes patent litigation is a shared responsibility, and clarity about roles prevents both duplication and gaps. In most pharma and biotech organisations, the general counsel or chief IP officer runs the operational process, issuing the request for proposals, coordinating interviews, and assembling the evaluation, while the board or a designated committee retains oversight of risk, budget authority and final approval for the largest matters.

A well-governed selection process typically allocates responsibilities as follows:

• Board or litigation committee. Sets risk tolerance, approves budget envelopes and settlement authority thresholds, and receives reporting on matter status and spend. For company-critical patents, the board should review the shortlist and the rationale for the final choice.
• General counsel. Owns the procurement process end to end: defining scope, issuing the RFP, running the scoring matrix, negotiating engagement terms, and presenting a recommendation to the board.
• Chief IP officer or head of patents. Assesses technical fit, the depth of the firm’s understanding of the science, its expert-management capability, and its familiarity with the specific patent family in dispute.
• Finance and procurement. Validates fee models, budget predictability and conflict-of-interest disclosures against internal policy.

Boards should insist on written reporting expectations from the outset: how often the firm will report, what budget-variance triggers require escalation, and who within the firm is accountable for those communications. Establishing this governance framework before engagement is far easier than retrofitting it mid-litigation, and it materially improves the board’s ability to oversee both risk and cost.

8 Questions Pharma & Biotech Boards Should Ask

The following eight questions form the core of a rigorous selection process. For each, we set out what a strong answer looks like, the red flags to watch for, the evidence you should request, and a suggested scoring band from 0 to 5. Ask every candidate firm the same questions, in the same order, so that responses can be compared consistently. This discipline is central to selecting IP counsel in Canada on an objective, defensible basis.

Q1: Do you have recent PM(NOC) experience, specifically post-2020 and current 2026 practice?

Evidence capsule: PM(NOC) proceedings are governed by the PM(NOC) Regulations, which set statutory components affecting litigation timing, including a stay of marketing approval whose duration is fixed by the Regulations.

PM(NOC) litigation is the defining category of pharma patent litigation Canada firms handle, and recency matters enormously because the procedural framework and the courts’ expectations evolve. Ask the firm to identify PM(NOC) files it has led in recent years, the role it played, the outcomes, and how the timelines ran against the statutory framework. Request anonymised examples of pleadings or case-management outcomes where confidentiality permits. A strong answer will demonstrate current, hands-on involvement and an understanding of how recent practice guidance and the post-2017 full-action framework affect strategy. The clearest red flag is a firm whose PM(NOC) credentials rest primarily on matters concluded before the 2017 amendments took effect.

Scoring: 5 for multiple lead-counsel PM(NOC) matters in recent years with documented outcomes; 0 for no verifiable recent PM(NOC) experience.

Q2: Do you have courtroom experience in Federal Court and appellate levels for pharma patents?

Most substantive patent litigation is heard in the Federal Court, with appeals to the Federal Court of Appeal and, where leave is granted, the Supreme Court of Canada. A firm that regularly settles but rarely tries cases may lack the courtroom credibility that shapes negotiation leverage. Ask for named examples where the firm’s lawyers acted as lead trial counsel, the results achieved, and any appellate work at the FCA or SCC level. Request the identity of the individuals who would actually appear, not just the firm’s aggregate record. Look for a track record that spans trial and appeal, since patent judgments are frequently appealed and appellate strategy must be considered from the outset.

A red flag is an inability to name recent trials or the individuals who conducted them. Scoring: 5 for demonstrated lead trial and appellate experience by the proposed team; 0 for no verifiable courtroom record.

Q3: How do you handle regulatory and health-authority interplay with Health Canada and CIPO?

In pharmaceutical disputes, patent litigation rarely proceeds in isolation from regulatory reality. Health Canada’s drug approval process and CIPO’s patent framework both shape the timing and strategy of litigation, and counsel must coordinate across these dimensions. Ask the firm how it factors regulatory milestones into litigation planning, how it structures cross-functional teams that include regulatory expertise, and whether it has managed matters where approval timing was decisive. Expect concrete examples of procedural coordination rather than general statements. The strongest firms treat regulatory strategy and litigation strategy as a single integrated plan. A red flag is a firm that treats Health Canada matters as somebody else’s problem. Scoring: 5 for demonstrated integrated regulatory-litigation coordination; 0 for no regulatory interface capability.

Q4: What is your approach to expert evidence and managing scientific experts?

Expert evidence often decides pharmaceutical and biotech patent cases, and managing scientific experts is a specialised skill. A biotech patent lawyer Canada boards can rely on will have a network of credible experts and a disciplined process for retaining, preparing and defending them. Ask the firm for the categories of experts it typically retains, how it manages concurrent expert evidence, and how it prepares experts for cross-examination and challenges to admissibility or reliability. Request sample expert-management approaches and, where permissible, examples of expert statements the firm has developed. Look for the ability to translate dense science into a persuasive courtroom narrative. A red flag is over-reliance on a single expert or an inability to describe an expert-management methodology.

Scoring: 5 for a deep expert bench and rigorous management process; 0 for ad hoc expert handling.

Q5: What is your experience with AI and digital evidence and current CIPO practice on e-evidence?

The volume and nature of digital evidence in patent litigation has grown sharply, and AI-generated material introduces new questions of authenticity, chain of custody and data integrity. Probe the firm’s experience handling AI-derived and large-scale digital evidence: how it establishes provenance, how it addresses data-integrity challenges, and what litigation-support and technology resources it can deploy. Ask about technology partnerships and the in-house or external capability to interrogate how digital evidence was created. A firm that can articulate a defensible methodology for AI and digital evidence signals readiness for the realities of 2026 litigation. The red flag is a firm that treats e-evidence purely as document review with no appreciation of authenticity and integrity issues.

Scoring: 5 for demonstrated AI and digital-evidence competence with supporting resources; 0 for none.

Q6: How do you staff matters, and who will be accountable?

Staffing determines both quality and cost. Ask for a project organisation chart showing who will lead, who will support, and how work is allocated across partners, senior counsel, associates and paralegals. Request the escalation model, the continuity plan if a key lawyer becomes unavailable, and the cross-jurisdictional resources available if the dispute reaches beyond a single province. A strong answer names an accountable lead partner with meaningful hours committed to the matter and a clear rationale for the mix of seniority. The classic red flag is a proposal that leans heavily on junior staffing while promising partner oversight that the fee estimate does not actually fund.

Scoring: 5 for a transparent, appropriately senior staffing model with named accountability; 0 for opaque staffing or evident junior-heavy delivery.

Q7: How do you price and manage budget predictability?

Budget predictability is a recurring board concern in ip litigation costs Canada discussions, and fee structure is where predictability is won or lost. Ask the firm to explain the fee models it offers, hourly, blended rates, fixed fees for defined phases, or hybrids, and to provide examples of prior litigation budgets alongside final spend. The gap between budgeted and actual cost is one of the most revealing pieces of evidence a firm can share. Request phase-based budgeting so that costs can be approved incrementally rather than as an open-ended commitment. A strong answer pairs a realistic budget with a transparent process for flagging variances early.

A red flag is unwillingness to share budget-versus-actual history or reliance on estimates with no phasing. Scoring: 5 for transparent phased budgeting with a strong track record of accuracy; 0 for open-ended hourly billing with no predictability tools.

Q8: How do you handle conflicts, insurance and litigation funding?

Before any substantive discussion, a firm must confirm it can act, free of conflicts and adequately insured. Ask about the firm’s conflict-checking process, its professional indemnity coverage, and whether it has experience working with third-party litigation funding where a matter warrants it. Professional conduct standards administered by provincial law societies and reflected in the Federation of Law Societies’ Model Code and Canadian Bar Association guidance set the baseline expectations for conflict management, and boards are entitled to ask how the firm meets them. Where litigation funding is contemplated, ask about the firm’s experience structuring such arrangements and any court-approval or disclosure considerations that may apply.

Useful negotiation levers include indemnity terms, caps on specific cost categories, and clear provisions on how conflicts arising later will be handled. A red flag is vagueness about conflicts or an inability to confirm insurance coverage. Scoring: 5 for rigorous conflict checks, confirmed coverage and relevant funding experience; 0 for unclear or evasive answers.

How to score proposals, scoring matrix for selecting IP counsel in Canada

A structured scoring matrix converts eight qualitative conversations into a comparison a board can act on. Assign each candidate a score from 0 to 5 against each criterion, then apply weightings that reflect your organisation’s priorities. For a company-critical PM(NOC) matter, PM(NOC) experience and Federal Court experience will usually carry the highest weight; for a matter turning on complex biological data, expert management and AI/evidence capability may weigh more heavily. Document your weightings before scoring so that the process is transparent and defensible.

A practical weighting approach for a typical pharma patent dispute might be: PM(NOC) experience 25%, Federal Court and appellate experience 20%, pharma/biotech technical fit 20%, AI and evidence capability 15%, budget predictability 15%, and conflicts/funding readiness 5%. Adjust these to your matter. The value of the matrix is not the arithmetic precision but the discipline it imposes: every firm is measured against the same criteria, and the board can see exactly why one firm outscored another. This is how boards move from an impression of the best IP law firms Canada offers to an evidence-based choice tailored to their specific dossier.

Comparison table: sample firm capability matrix

The table below illustrates how a completed scoring matrix might look for three hypothetical candidate firms. The scores are illustrative only and are intended to show the structure, not to represent any real firm.

In this illustration, Firm A leads on the highest-weighted criteria, while Firm B is stronger on technical fit and evidence capability. A board would interpret these results against the specific demands of its matter rather than simply choosing the highest raw total.

Costs, fee arrangements and funding options for pharma patent litigation

Understanding cost drivers is essential to budgeting, and pharma patent litigation carries several distinctive ones. Expert evidence is often the single largest variable cost, driven by the number and seniority of experts and the complexity of the science. Discovery and evidence handling, particularly where large volumes of digital or AI-derived material are involved, can also drive significant spend. The statutory timeline components of PM(NOC) proceedings under the PM(NOC) Regulations shape the cadence of work and therefore the timing of costs, and Federal Court procedure influences how litigation phases unfold.

Fee arrangements generally fall into a few categories, and boards should assess each against their appetite for predictability:

• Hourly billing. Maximum flexibility but the least predictability; best paired with phase budgets and variance reporting.
• Blended rates. A single rate across the team simplifies forecasting and can reduce the incentive to over-staff with senior lawyers.
• Fixed or capped fees. Predictability for defined phases, shifting some cost risk to the firm; requires a well-scoped mandate to work fairly.
• Litigation funding. Third-party funding can preserve capital for companies pursuing meritorious claims, though it introduces its own governance, court-approval and disclosure considerations.

On the frequently asked question of how much IP lawyers earn, the more useful lens for a board is not individual compensation but expected hourly or blended rates and total litigation budget. Cost recovery is also relevant: the Federal Court can award costs to a successful party under its rules and discretion, and the potential for recovery, or exposure, should feature in any budget analysis. Because market rate data changes, boards should benchmark current figures against recruiting and market sources rather than relying on fixed numbers, and should focus procurement discussions on budget-versus-actual history from each candidate firm.

Due diligence, red flags and required documents to request

Before signing an engagement letter, boards should complete focused due diligence on their preferred firm. Professional conduct and conflict expectations are set out by provincial law societies and reflected in the Federation of Law Societies’ Model Code of Professional Conduct and Canadian Bar Association guidance, and it is reasonable to verify that a firm meets them. The following documents and checks form a practical due-diligence set:

• Conflict clearance. Written confirmation that the firm has run a conflict check against your organisation, its affiliates and the opposing parties.
• Disciplinary and insurance verification. Confirmation of good standing with the relevant law society and evidence of adequate professional liability coverage.
• Lead counsel CVs. Detailed profiles of the specific lawyers who will run the matter, including their recent PM(NOC) and Federal Court work.
• Sample engagement letter. A specimen letter so terms, fees and reporting expectations can be reviewed before commitment.
• Representative work product. Anonymised or redacted examples of pleadings, expert-management approaches or budgets, where confidentiality permits.

The recurring red flags across this process are worth stating plainly: no verifiable recent PM(NOC) examples; an inability to name the individuals who conducted recent trials; no coherent expert-management methodology; junior-heavy staffing dressed up as partner-led; and reluctance to share budget-versus-actual history. Any one of these should prompt closer scrutiny; several together should prompt reconsideration. Rigorous due diligence is the final safeguard in selecting IP counsel in Canada, and it is far cheaper to conduct now than to remedy later.

Conclusion, next steps and procurement resources

Selecting the right ip litigation lawyers Canada boards will trust with company-critical patents is a governance decision that rewards structure. The eight questions in this guide, applied consistently and scored against weighted criteria, turn an impressionistic choice into a defensible one. Ground the process in evidence you can verify, recent PM(NOC) files, named trial counsel, expert-management methodology, digital and AI-evidence capability, transparent budgeting, and clean conflict and insurance checks, and align the whole exercise with the regulatory realities of 2026. To operationalise this, build an RFP around the eight questions, distribute the scoring matrix to your evaluation team, and complete due diligence before signing. For boards and general counsel ready to run a structured selection process, the RFP template and scoring matrix, together with further guidance on the IP Litigation, Canada practice page and the GLE lawyer directory for Canada IP litigation, provide the tools to move from shortlist to confident appointment.

Sources

1. Canadian Intellectual Property Office (CIPO)
2. Patented Medicines (Notice of Compliance) Regulations (SOR/93-133), Justice Laws
3. Patent Act (R.S.C., 1985, c. P-4), Justice Laws
4. Federal Courts, Decisions Portal
5. Supreme Court of Canada
6. Health Canada
7. Federation of Law Societies of Canada, Model Code of Professional Conduct
8. Canadian Bar Association (CBA)
9. Law Society of Ontario (LSO)